Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Condylomata Acuminata 3Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Keratosis, Actinic 2Head and Neck Neoplasms 2Breast Neoplasms 2Wounds and Injuries 1Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Sexually Transmitted Diseases 1Parapsoriasis 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Non-Melanoma Skin Cancers 1Lymphoma, Follicular 1Keratosis, Seborrheic 1Hypogonadism 1Hemangioma, Cavernous 1Hemangioma 1Fatigue 1Exanthema 1Eunuchism 1Dermatitis, Contact 1

Interventions

Fulvestrant 2ruxolitinib 1ceterizine hydrochloride 1capivasertib 1benralizumab 1Triamcinolone Acetonide 1Tetracycline 1Sirolimus 1Prednisone 1Panitumumab 1Minocycline 1Loperamide 1Irinotecan 1IFL protocol 1Hydrocortisone 1Gels 1Erlotinib Hydrochloride 1Doxycycline 1Dapsone 1Clindamycin 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Exanthema × Gels × Clear all
NCT00343187 2011-05-30

A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash

Allergan

Phase 2 Terminated
2 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡